Introduction
The pharmaceutical and life sciences (PLS) industry is expected to have an active year for mergers and acquisitions in 2025. Deal values and volumes are predicted to increase due to anticipated rate cuts by the Federal Reserve and the resolution of challenges following the recent election. Transactions between $5 billion and $15 billion are expected to see sustained activity, though geopolitical factors could create headwinds.
Key Subsectors to Watch:
- Pharma: Pharma companies will likely seek to fill loss of exclusivity gaps in their product pipelines. The success of GLP-1s in 2024 will drive interest in the cardio-metabolic market, and companies may use M&A to enter this space.
- Medtech: Increased M&A activity is anticipated in emerging categories like robotics, data, and AI as companies look to reinvent their business models.
- Biotech: Early to mid-stage biotech companies with innovative products will become attractive buyout targets. Radiopharmaceuticals and immunology are expected to see healthy activity, with China-to-West licensing deals continuing due to the Biosecure Act and clinical innovation in China.
- Services/Other: Renewed interest in consolidation within contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) is expected as participants seek unique capabilities and specialty niches to accelerate time to market.
Potential Regulatory Shifts: A new administration could bring significant regulatory policy changes, especially with potential leadership changes at the Department of Justice (DOJ) and Federal Trade Commission (FTC), which could resolve concerns that previously prevented larger deals. New tariffs and regulatory actions, like the Biosecure Act, could restrict multinational supply chains and cross-border investment.
Keeping Pace with Advances:
Individual stock performance has been heavily driven by exposure to specific therapeutic areas; those with a presence in GLP-1s have performed well. Investors are weighing the right time to acquire high-potential therapeutic classes like immunology and oncology at attractive prices, with significant dry powder available.
Private Equity (PE) Considerations:
Many PE investors have held onto portfolio companies longer than usual due to economic uncertainty. This backlog is expected to resolve in 2025 as PE firms look for exits to return capital or reinvest, which is a positive sign for the sector.
